Phase 3, Randomized, Double-Blind, Active-Comparator (Darbepoetin Alfa) Study of Oral Roxadustat in CKD Patients with Anemia on Hemodialysis in Japan

BACKGROUND: Roxadustat is an oral hypoxia-inducible factor prolyl hydroxylase inhibitor approved in China for dialysis-dependent CKD anemia. METHODS: This phase 3, 24-week, double-blind, double-dummy study evaluated roxadustat’s noninferiority to darbepoetin alfa for hemodialysis-dependent CKD anemi...

全面介紹

Na minha lista:
書目詳細資料
發表在:J Am Soc Nephrol
Main Authors: Akizawa, Tadao, Iwasaki, Manabu, Yamaguchi, Yusuke, Majikawa, Yoshikatsu, Reusch, Michael
格式: Artigo
語言:Inglês
出版: American Society of Nephrology 2020
主題:
Clinical Research
在線閱讀:https://ncbi.nlm.nih.gov/pmc/articles/PMC7350993/
https://ncbi.nlm.nih.gov/pubmed/32493693
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1681/ASN.2019060623
標簽: 添加標簽
沒有標簽, 成為第一個標記此記錄!

相似書籍